¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"specific absorption rate"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • species-specific reactivity
    Á¾Æ¯À̹ÝÀÀ¼º
  • specific
    1. ƯÀÌ-, ƯÁ¤- 2. Á¾-
  • specific action
    ƯÀÌÀÛ¿ë
  • specific activity
    1. ºñ¹æ»ç´É 2. ºñ(Ýï)Ȱ¼ºµµ, °íÀ¯È°¼ºµµ
  • specific antagonist
    ƯÀÌ´ëÇ×Á¦
  • specific antigen
    ƯÀÌÇ׿ø
  • specific capsular reaction
    ƯÀÌÇǸ·¹ÝÀÀ
  • specific charge
    ºñÀüÇÏ, °ßÁÜÀüÇÏ
  • specific compliance
    ºñ¼øÀÀµµ
  • specific conductivity
    ºñÀüµµÀ²
  • specific electric conductivity
    ºñÀü±âÀüµµÀ²
  • specific granule
    ƯÀ̰ú¸³
  • specific gravity
    ºñÁß
  • specific gravity test
    ºñÁß°Ë»ç
  • specific heat
    ºñ¿­(Ýïæð)
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • standardized death rate
    Ç¥ÁØÈ­»ç¸Á·ü
  • survival rate
    »ýÁ¸·ü
  • tidal rate
    È£Èí¼ö
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • specific pathogen free animal
    ƯÁ¤¹«º´¿øÃ¼µ¿¹°
  • type specific antigen
    ÇüƯÀÌÇ׿ø
  • blood group specific substance
    Ç÷¾×ÇüƯÀ̹°Áú
  • specific charge
    °ßÁÜÀüÇÏ, ºñÀüÇÏ
  • specific compliance
    ƯÀÌź¼º, ƯÀÌÀ¯¼øµµ, ƯÀÌÀÀ¶ô
  • specific conductivity
    ºñÀüµµÀ²
  • specific electric conductivity
    ºñÀü±âÀüµµÀ²
  • donor-specific phage
    Á¦°øÃ¼Æ¯ÀÌÆÄÁö, ÁÖ°ÔÆ¯ÀÌÆÄÁö
  • specific disease
    ƯÀÌÁúȯ
  • specific reading disability
    ƯÁ¤ÀбâÀå¾Ö
  • group-specific
    ±ºÆ¯ÀÌ-
  • specific granule
    ƯÀ̰ú¸³
  • specific gravity
    ºñÁß
  • specific heat
    ƯÀÌ¿­
  • specific humidity
    ºñ½Àµµ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • GFR= glomerular filtration rate
    »ç±¸Ã¼(ÞêϹô÷)°Å¸§·ü(×È).
  • GFR= glomerular filtration rate
    »ç±¸Ã¼°Å¸§·ü.
  • Heart rate
    ½É¹Ú¼ö(ãýÚÑâ¦)
  • MVR=£¾maximus voiding rate
    ÃÖ´ë¹è´¢À².
  • Westergren sedimentation rate
    ¿þ½ºÅͱ׷»Ä§°­¼Óµµ
  • absorbed dose rate
    Èí¼ö¼±·®À²
  • actual death rate
    ½ÇÁ¦»ç¸Á·ü(ËàÌ¡Ë×ËÎËô).
  • adjusted death rate
    Á¶Á¤»ç¸Á·ü.
  • air kerma-rate constant
    °ø±âÄ¿¸¶À²»ó¼ö
  • alveolar ventilation rate
    ÆóÆ÷ȯ±âºñ(¡­üµÑ¨Ýï)
  • arterial perfusion rate
    µ¿¸Æ°ü·ùÀ²
  • fractional fibrinogen catabolic rate
    ºÐȹº° ¼¶À¯¼Ò¿ø ´ë»çÀ².
  • frame rate
    È­¸éÀ²
  • frame rate
    È­¸é ¹ß»ýÀ² (ûþØü Û¡ßæëÒ)
  • general fertility rate
    ÀϹÝÃâ»êÀ².
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • lacuna absorption
    Èí¼ö¼Ò¿Í.
  • mass energy absorption coefficient
    Áú·®¿¡³ÊÁöÈí¼ö°è¼ö
  • maximum absorption
    ÃÖ´ëÈí¼ö.
  • mineral absorption
    ¹«±âÁú Èí¼ö
  • moisture absorption
    Èí½À(ýåã¥).
  • percutaneous absorption
    °æÇÇ Èí¼ö
  • photoelectric absorption
    ±¤ÀüÈí¼ö
  • radiant energy absorption
    º¹»ç(¹æ»ç)¿¡³ÊÁöÈí¼ö
  • radiofrequency absorption
    ¶óµð¿ÀÆÄ Èí¼ö
  • resonance absorption
    °ø¸íÈí¼ö
  • resonance absorption
    °ø¸íÈí¼ö(ÍìÙ°ýåâ¥).
  • selective absorption
    ¼±ÅÃÈí¼ö(¡­ýåâ¥).
  • sound absorption
    À½Çâ Èí¼ö
  • water absorption
    ¼öºÐÈí¼ö(â©ÝÂýåâ©).
  • xylose absorption test
    ½Ç·Î½ºÈí¼ö½ÃÇè(¡­ýåâ¥ãËúÐ).
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • specific dynamic action
    ƯÀÌ µ¿Àû ÀÛ¿ë(÷åì¶ÔÑîÜíÂéÄ)
  • specific extinction coefficient
    ºñÈí±¤ °è¼ö(ÝïýåÎÃÌõâ¦)
  • specific gravity
    ºñÁß(Ýïñì)
  • specific heat
    ºñ¿­(Ýïæð)
  • specific immune suppression
    ƯÀÌ ¸é¿ª¾ï¾Ð(÷åì¶Øóæ¹åääâ)
  • specific immunity
    ƯÀ̸鿪(÷åì¶Øóæ¹)
  • specific interaction theory
    ƯÀÌ »óÈ£ÀÛ¿ëÀÌ·Ð(÷åì¶ßÓû»íÂéÄ×âÖå)
  • specific ionization
    ºñ(Ýï) ÀÌ¿ÂÈ­(ûù)
  • specific radioactivity
    ºñ¹æ»ç´É(ÝïÛ¯ÞÒÒö)
  • specific refractive index increment
    ƯÀÌ ±¼ÀýÁö¼ö Áõ°¡(÷åì¶ÏÝï¹ò¦â¦ñòÊ¥)
  • specific retention volume
    ºñ Àú·ù ¿ëÀû(ÝïîÍ×µé»îÝ)
  • specific rotation
    ºñ¼±±¤µµ(ÝïàÁÎÃÓø)
  • specific rotatory power
    ºñ¼±±¤·Â(ÝïàÁÎÃÕô)
  • specific substrate concentration
    ƯÀÌ ±âÁú³óµµ(÷åì¶ÐñòõÒØÓø)
  • specific viscosity
    ºñÁ¡µµ(ÝïïÄÓø)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
ASFR age-specific fertility rate
FTA-ABS test Fluorescent Treponemal Antibody ABSorption test
IDA   1) Imino-Diacetic Acid
  2) Iron Deficiency Anemia
   &nb...
AA abdominal aorta; acetic acid; achievement age; active alcoholic; active assistive [range of motion];...
AAS Aarskog-Scott [syndrome]; acid aspiration syndrome; alcoholic abstinence syndrome; American Academy ...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
TAS Tellegen Absorption Scale
XAFS X-Ray Absorption Fine Structure
XANES X-ray Absorption Near Edge Structure
XAS X-ray Absorption Spectroscopy
FAAS flame atomic absorption spectrometry
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • specific region
    ƯÀÌ ºÎÀ§
  • specific tender point site
    ƯÁ¤ ¾ÐÅëÁ¡
  • specific weight
    ºñÁß
  • tumor specific transplantation
    Á¾¾ç ƯÀ̼º À̽Ä
  • virus-specific surface antigen
    ¹ÙÀÌ·¯½º ƯÀ̼º Ç¥¸é Ç׿ø ¹ÙÀÌ·¯½º
  • absorptace rate
    Èí¼öÀ²
    ÀÎü¿¡ Á¶»çµÇ´Â ¹æ»ç¼±¿¡ ´ëÇØ ÀÎü¿¡ Èí¼öµÇ´Â ¹æ»ç¼± ¿¡³ÊÁöÀÇ ºñÀ².
  • adjusted death rate
    Á¶Á¤ »ç¸Á·ü
  • attack rate
    ¹ßº´·ü, ÀÌȯÀ²
  • basal metabolic rate
    ±âÃÊ ´ë»çÀ²
    ½Ä»ç ÈÄ ÀÏÁ¤ ½Ã°£ÀÌ Áö³ª°í ³ª¼­ÀÇ ¾ÈÁ¤ »óÅ¿¡¼­ÀÇ »ê¼Ò ¼Òºñ ¼Óµµ.
  • cardiac rate
    ½É¹Ú ¼ö
    µ¿ÀǾî=heart rate.
  • caries incidence rate
    ¿ì½Ä¹ß»ýÀ²
    ÀÏÁ¤ÇÑ ±â°£¿¡ ¹ß»ýÇÏ´Â ¿ì½Ä ¹ß»ýÀ², ¨ç Æò±Õ ³â°£ ¿ì½Ä¹ß»ýÀ² =
  • case fatality rate
    Ä¡¸í·ü
  • conversion rate
    ÀüȯÀ²
  • D.E.F. rate
    µð.ÀÌ.¿¡ÇÁ
    Decayed Extractlion, FilledÀÇ ¾àÀÚ.
  • daily secretion rate
    ÀÏÀÏ ºÐºñ·®
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
prenylated peptide-specific endoprotease <enzyme> Cleaves c-terminal tripeptide from prenylated protein having c-terminal sequence caax; race is rac and a-factor converting enzyme with same activity
Registry number: EC 3.4.14.-
Synonym: prenylated protein endoprotease, race enzyme, isoprenylated protein endopeptidase, isoprenylated protein endoprotease
(26 Jun 1999)
cytosol non-specific dipeptidase <enzyme> Also referred to as peptidase a (see synonym to penicillopepsin, EC 3.4.23.20)
Registry number: EC 3.4.13.-
Synonym: glycyl-l-leucine hydrolase, glycylleucine dipeptidase, gly-leu dipeptide peptidase, dipeptide hydrolase, glycyl-leucine dipeptidase
(26 Jun 1999)
cytotoxic T lymphocyte-specific serine protease <enzyme> Structural sequence given in first source
Registry number: EC 3.4.21.-
Synonym: cytotoxic t lymphocyte-specific serine protease ccp I, cytotoxic t lymphocyte specific serine protease ccp II, mast cell protease type II
(26 Jun 1999)
proline-specific dipeptidylcarboxypeptidase <enzyme> From streptomyces species; removes diproline form c-terminus of proline-containing peptides such as boc-pro-pro-pro-pro or leu-pro-pro-pro-pro-pro
Registry number: EC 3.4.15.-
Synonym: pro-dpp-carboxypeptidase
(26 Jun 1999)
prostate-specific antigen <tumour marker> A simple blood test used to detect prostate cancer in men. The test measures a specific antigen normally secreted by the prostate. If cancer is developing, the prostate secretes greater amounts of prostate-specific antigen. This test is recommended for men with an enlarged prostate and an increased risk of prostate cancer.
It is an enzyme that is produced by epithelial cells of both benign and malignant prostate tissue. It is an important marker for the diagnosis of prostate cancer.
It is a single chain 31 kilodalton glycoprotein with 240 amino acid residues and 4 carbohydrate side chains that is a kallikrein protease.
It is found in normal seminal fluid and produced by the prostatic epithelial cells.
Elevated levels in blood serum are associated with prostatic enlargement and prostatic adenocarcinoma, and this allows early detection of cancer in many cases. In about 70% of cases, the rise is due to a cancerous condition.
No large scale clinical studies have been completed to assess the impact of testing on survival from prostate cancer, and the medical and economic value of testing remain uncertain.
Acronym: PSA
Registry number: EC 3.4.21.77
(22 Sep 2002)
pyrimidine-guanine sequence-specific ribonuclease <enzyme> From yolk granules of adult rana catesbeiana oocytes
Registry number: EC 3.1.27.-
Synonym: rc-rnase, rana catesbeiana rnase
(26 Jun 1999)
site-specific mutagenesis <cell culture, molecular biology> An in vitro technique in which an alteration is made at a specific site in a DNA molecule, which is then reintroduced into a cell. Various techniques are used, for the cell biologist, a very powerful approach to determining which parts of a protein or nucleotide sequence are critical to function.
(18 Nov 1997)
site specific mutation An alteration of the structure of a gene at a specific sequence, usually referring to experimentally produced changes in gene sequence.
(05 Mar 2000)
site-specific recombination <molecular biology> A type of recombination that occurs between two specific short DNA sequences present in the same or in different molecules. An example is the integration and excision of _ prophage.
(18 Nov 1997)
soluble specific substance A soluble type-specific polysaccharide produced during active growth of virulent pneumococci composing a large part of the capsule.
Synonym: pneumococcal polysaccharide, soluble specific substance, specific soluble polysaccharide, specific soluble sugar.
(05 Mar 2000)
species-specific Applying only to a particular species, said of effects that vary depending on the species in question.
(09 Oct 1997)
species-specific antigen Antigenic components in the tissues and fluids of members of a species of animal, by means of which various species may be immunologically distinguished; e.g., serum albumin of horses is immunologically different from that of man, dogs, sheep, and so on.
(05 Mar 2000)
specific 1. Pertaining to a species.
2. Produces by a single kind of microorganism.
3. A remedy specially indicated for any particular disease.
4. <immunology> Pertaining to the special affinity of antigen for the corresponding antibody.
Origin: L. Specificus
(18 Nov 1997)
specific absorbance Absorbance per unit of concentration.
See: specific absorption coefficient.
(05 Mar 2000)
specific action The action of a drug or a method of treatment which has a direct and especially curative effect upon a disease, e.g., the action of vitamin B12 in pernicious anaemia.
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 8 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • rate
    ºñÀ²;¿ä±Ý;½Ã¼¼;°¡°Ý;Æò°¡;¼Óµµ;Áøµµ;ÇÏ·çÀÇ ¿ÀÂ÷(½Ã°èÀÇ);¼¼±Ý;Áö¹æ¼¼;µî±Þ(¹è.¼±¿øÀÇ)...µî;Á¾·ù;Æò°¡ÇÏ´Ù;¾î¸²Àâ´Ù;...À¸·Î ¾Ë´Ù;À̶ó°í »ý°¢ÇÏ´Ù;(°ú¼¼¸¦ ¸ñÀûÀ¸·Î)...À» Æò°¡ÇÏ´Ù;...¿¡°Ô Áö¹æ¼¼¸¦ °úÇÏ´Ù;(¼±¿ø.¼±¹ÚÀÇ)µî±ÞÀ» Á¤ÇÏ´Ù;±Ô°ÝÀ» Á¤ÇÏ´Ù;(±â°èÀÇ)¿ÀÂ÷¸¦ Ãø
  • rate base
    (ÀâÁöÀÇ)º¸Áõ ºÎ¼ö(À̸¦ ¹ÙÅÁÀ¸·Î ±¤°í¿ä±ÝÀÌ Á¤ÇØÁü)
  • rate card
    ±¤°í ¿äÀ²Ç¥(±¤°í ¿ä±Ý.°ÔÀç ȸ¼ö.¿ø°í ¸¶°¨ÀÏ µîÀ» ¸í½ÃÇÑ Ç¥)
  • rate meter
    (°è¼ö±âÀÇ)°è¼öÀ²°è
  • rediscount rate
    (¾îÀ½ÀÇ)ÀçÇÒÀÎÀ²
  • second rate
    2·ùÀÇ;2µîǰ;...¸¸ ¸øÇÑ
  • second rate
    2·ùÀÇ;¿­µîÇÑ;Æò¹üÇÑ
  • third rate
    3µîÀÇ;¿­µîÇÑ
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
ÅëÇÕ°Ë»ö ¿Ï·á